Last reviewed · How we verify

NCT06294886

Vaginal Fluid Collection for Detection of Endometrial Cancer

Status unknown Last updated 7 March 2024
What this trial tests

trial testing Screening test to detect endometrial cancer and precancer in Endometrial Cancer in 40 participants. Status unknown.

Timeline
19 February 2024
Primary endpoint
1 June 2024
1 June 2024

Quick facts

Lead sponsorInnovis LLC
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date19 February 2024
Primary completion1 June 2024
Estimated completion1 June 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Innovis LLC

Who can join

18 and older, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to obtain de-identified vaginal fluid specimens from participants with an endometrial tissue biopsy-based histopathological diagnosis of endometrial cancer (EC), endometrial hyperplasia (AEH) with atypia or endometrial intraepithelial neoplasia (EIN). The samples will be used for the purpose of research and development of a new molecular diagnostic test for the detection of EC, AEH and EIN.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

Other Innovis LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06294886.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing